Literature DB >> 2433042

Interactions of antinicotinic acetylcholine receptor antibodies with rat brain and muscle antigenic determinants.

R J Lukas.   

Abstract

Studies were performed to determine whether antibodies prepared against nicotinic acetylcholine receptors (nAcChoR) from electric tissue are reactive toward nAcChoR-like antigenic determinants in rat brain. Reference experiments involved the use of Torpedo electroplax and rat innervated muscle as tissue controls and an anti-alpha-bungarotoxin antiserum as a probe for curaremimetic neurotoxin binding sites. As evinced by their ability to inhibit immunoprecipitation of Torpedo nAcChoR, brain or muscle membranes specifically interact with polyclonal antisera raised against Electrophorus electroplax nAcChoR. When the extent of polyclonal anti-nAcChoR antibody binding to muscle membranes is measured by protein A binding protocols, receptor-like antigenic determinants and toxin binding sites are found to be present in approximately equal quantities. In contrast, nAcChoR-like antigenic determinants on rat brain membranes are present at concentrations in excess of those of toxin binding sites. The results are consistent with the earlier observation that some antibodies prepared against nAcChoR from peripheral tissues recognize rat brain high-affinity alpha-bungarotoxin binding sites. The results also suggest the existence of nAcChoR-like entities in brain that do not bind toxin with a high affinity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2433042     DOI: 10.1007/bf00711114

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  25 in total

1.  Immunochemical and pharmacological distinctions between curaremimetic neurotoxin binding sites of central, autonomic, and peripheral origin.

Authors:  R J Lukas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

2.  Immunohistochemical localization of monoclonal antibodies to the nicotinic acetylcholine receptor in chick midbrain.

Authors:  L W Swanson; J Lindstrom; S Tzartos; L C Schmued; D D O'Leary; W M Cowan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

3.  Central nervous-system involvement in experimental autoimmune myasthenia gravis.

Authors:  B W Fulpius; A Fontana; S Cuénoud
Journal:  Lancet       Date:  1977-08-13       Impact factor: 79.321

4.  Adipsia and aphagia elicited by intracerebroventricular injections of antiacetylcholine receptor antibodies.

Authors:  R Tarrab-Hazdai; H Edery
Journal:  Exp Neurol       Date:  1980-03       Impact factor: 5.330

5.  Electrophysiological, behavioral, and chemical evidence for a noncholinergic, stereospecific site for nicotine in rat brain.

Authors:  L G Abood; K Lowy; A Tometsko; H Booth
Journal:  J Neurosci Res       Date:  1978       Impact factor: 4.164

6.  Interactions of anti-nicotinic acetylcholine receptor antibodies at alpha-bungarotoxin binding sites across species and tissues.

Authors:  R J Lukas
Journal:  Brain Res       Date:  1986-11       Impact factor: 3.252

7.  [Antibodies against nicotine-like acetylcholine receptors of central nervous system and muscles in epileptics with IgA deficiency].

Authors:  A Fontana; B W Fulpius; S Cuénoud
Journal:  Schweiz Med Wochenschr       Date:  1978-08-26

8.  Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate.

Authors:  M J Marks; A C Collins
Journal:  Mol Pharmacol       Date:  1982-11       Impact factor: 4.436

9.  Histological localization of binding sites of alpha-bungarotoxin and of antibodies specific to acetylcholine receptor in goldfish optic nerve and tectum.

Authors:  M Schwartz; D Axelrod; E L Feldman; B W Agranoff
Journal:  Brain Res       Date:  1980-07-21       Impact factor: 3.252

10.  Monoclonal anti-acetylcholine-receptor antibodies directed against the cholinergic binding site.

Authors:  D Mochly-Rosen; S Fuchs
Journal:  Biochemistry       Date:  1981-09-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.